Adicet Bio, Inc. (NasdaqCM: ACET)
Health Care · Biotechnology · US
$9.10
-0.98% today · -19.2% 1Y
Adicet Bio, Inc. (NasdaqCM: ACET) operates in the Biotechnology industry within the Health Care sector. The company is valued at $98.92M and employs 102 people.
Over the last twelve months the share price has lost 19.2%, trading between 6.01 and 17.44.
Tweenvest scores Adicet Bio, Inc. across four factors: quality 29/100. Its strongest factor is quality.
ACET price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $98.92M
- Revenue (TTM)
- —
- P/E
- —
- EPS
- -10.52
- Dividend yield
- —
- Beta (5Y)
- 1.59
- 52-week high
- $17.44
- 52-week low
- $6.01
- Avg volume (3M)
- —
- Shares outstanding
- 10.76M
- Employees
- 102
- Next earnings
- —
About Adicet Bio, Inc.
Adicet Bio, Inc. is a biotechnology firm dedicated to pioneering allogeneic gamma delta T cell therapies, aiming to treat cancer and various other diseases. The company’s strategy involves engineering gamma delta T cells with chimeric antigen receptors (CARs) and T cell receptor-like antibodies. This advanced modification is designed to achieve more precise targeting of tumors, enhance the body's natural and acquired immune responses against cancer, and provide sustained therapeutic benefits for patients. ADI-001, its most advanced therapeutic candidate, is presently in a Phase I clinical trial for individuals with non-Hodgkin's lymphoma. Additionally, Adicet Bio is developing ADI-002, which is undergoing preclinical investigations for its potential in treating a range of solid tumors. The company is headquartered in Boston, Massachusetts.
- ISIN
- US0070022076
- Founded
- 2014
- Listed since
- Jan 26, 2018
- Exchange
- Nasdaq Capital Market
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $469.68B | $266.72 | +0.35% |
| Amgen Inc.NasdaqGS: AMGN | $239.09B | $445.50 | +0.74% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $184.47B | $148.77 | +1.38% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $140.13B | $552.00 | -0.15% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $83.24B | $832.63 | -0.11% |
| argenx SEENXTBR: ARGX | $64.17B | €897.60 | +2.09% |
| Moderna, Inc.NasdaqGS: MRNA | $63.41B | $158.06 | -0.48% |
| CSL LimitedASX: CSL | $59.49B | AU$173.64 | +2.68% |
Figures last refreshed Aug 18, 2026.